Literature DB >> 11790288

Genetic targeting of the renin-angiotensin system for long-term control of hypertension.

Beverly L Metcalfe1, Mohan Raizada, Michael J Katovich.   

Abstract

Although traditional approaches are effective for the treatment and control of hypertension, they have not succeeded in curing the disease, and have therefore reached a plateau. As a result of the completion of the Human Genome Project and the continuous advancement in gene delivery systems, it is now possible to investigate genetic means for the treatment and possible cure for hypertension. In this review we discuss the potential of genetic targeting of the renin-angiotensin system for the treatment of hypertension. We provide examples of various approaches that have used antisense technology with a high degree of success. We focus on our own research, which targets the use of antisense of the angiotensin type I receptor in various models of hypertension. Finally, we discuss the future of antisense technology in the treatment of human hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11790288     DOI: 10.1007/s11906-002-0049-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  53 in total

1.  Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery.

Authors:  K F Lin; L Chao; J Chao
Journal:  Hypertension       Date:  1997-09       Impact factor: 10.190

Review 2.  Viral vectors for gene therapy.

Authors:  P D Robbins; S C Ghivizzani
Journal:  Pharmacol Ther       Date:  1998-10       Impact factor: 12.310

3.  Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense.

Authors:  B Kimura; D Mohuczy; X Tang; M I Phillips
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

4.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.

Authors:  L Naldini; U Blömer; F H Gage; D Trono; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Gene transfer of endothelial nitric oxide synthase reduces angiotensin II-induced endothelial dysfunction.

Authors:  H Nakane; F J Miller; F M Faraci; K Toyoda; D D Heistad
Journal:  Hypertension       Date:  2000-02       Impact factor: 10.190

6.  Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats.

Authors:  J Chao; J J Zhang; K F Lin; L Chao
Journal:  Hum Gene Ther       Date:  1998-01-01       Impact factor: 5.695

7.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.

Authors:  R Morishita; G H Gibbons; K E Ellison; M Nakajima; L Zhang; Y Kaneda; T Ogihara; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

Review 8.  Blood pressure, systolic and diastolic, and cardiovascular risks. US population data.

Authors:  J Stamler; R Stamler; J D Neaton
Journal:  Arch Intern Med       Date:  1993-03-08

9.  Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses.

Authors:  P Gohlke; M Stoll; V Lamberty; T Mattfeld; G Mall; P van Even; P Martorana; T Unger
Journal:  J Hypertens Suppl       Date:  1992-08

10.  Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats.

Authors:  P Gohlke; W Linz; B A Schölkens; G Wiemer; T Unger
Journal:  Hypertension       Date:  1996-09       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.